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OBJECTIVE — To evaluate the association of successive percutaneous coronary intervention
(PCI) modalities with balloon angioplasty (BA), bare-metal stent (BMS), drug-eluting stents
(DES), and pharmacotherapy over the last 3 decades with outcomes among patients with dia-
betes in routine clinical practice.
RESEARCHDESIGNANDMETHODS — Weexaminedoutcomesin1,846patientswith
diabetes undergoing de novo PCI in the multicenter, National Heart, Lung, and Blood Institute–
sponsored 1985–1986 Percutaneous Transluminal Coronary Angioplasty (PTCA) Registry and
1997–2006 Dynamic Registry. Multivariable Cox regression models were used to estimate the ad-
justed risk of events (death/myocardial infarction [MI], repeat revascularization) over 1 year.
RESULTS — Cumulative event rates for postdischarge (31–365 days) death/MI were 8% by
BA,7%byBMS,and7%byDESuse(P0.76)andforrepeatrevascularizationwere19,13,and
9% (P  0.001), respectively. Multivariable analysis showed a signiﬁcantly lower risk of repeat
revascularizationwithDESusewhencomparedwiththeuseofBA(hazardratio[HR]0.41[95%
CI0.29–0.58])andBMS(HR0.55[95%CI0.39–0.76]).Afterfurtheradjustmentfordischarge
medications,thelowerriskfordeath/MIwasnotstatisticallysigniﬁcantforDESwhencompared
with BA.
CONCLUSIONS — In patients with diabetes undergoing PCI, the use of DES is associated
with a reduced need for repeat revascularization when compared with BA or BMS use. The
associated death/MI beneﬁt observed with the DES versus the BA group may well be due to
greater use of pharmacotherapy.
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T
he practice of percutaneous coro-
nary intervention (PCI) has evolved
rapidly in the past 3 decades, with
technologicaladvancementsfromballoon
angioplasty (BA) to bare-metal stents
(BMS) and the more recent drug-eluting
stents (DES) (1). Comparisons of device-
speciﬁc outcomes have yielded similar
results, with a recent meta-analysis re-
porting a signiﬁcant reduction in the rate
of target lesion revascularization, but not
mortality, with DES use compared with
BMS use (2).
Coronaryangioplastyinpatientswith
diabetes has been shown to have a higher
rate of infarction and a greater need for
additional revascularization procedures
(3). In a large consecutive series of pa-
tients treated by elective stent implanta-
tion,patientswithdiabeteswereathigher
risk for in-hospital mortality and subse-
quent revascularization, which ultimately
resulted in a signiﬁcantly lower cardiac
event-free survival rate (4). Yet, the bene-
ﬁt of DES over BMS remains unclear. A
pooled analysis (5) reported a signiﬁcant
differenceinsurvivalinfavorofBMSover
theDES,whereasnosigniﬁcantdifference
inmortalitywasobservedinanotheranal-
ysis of 14 randomized controlled trials
(6).Giventheseinconsistentﬁndingsand
the growing percentage of diabetic pa-
tients undergoing PCI, the impact of ad-
vances in PCI technology and adjunct
improvement in pharmacotherapy on
outcomes in patients with diabetes needs
to be assessed.
We, therefore, investigated the effec-
tiveness of PCI in patients with diabetes
by comparing 1-year rates of death/
myocardial infarction (MI) and repeat re-
vascularization across the three device
modalities: BA, BMS, and DES. Data from
the multicenter, National Heart, Lung,
and Blood Institute (NHLBI)-sponsored
1985–1986 Percutaneous Transluminal
Coronary Angioplasty (PTCA) Registry
and the 1997–2006 Dynamic Registry
were used for this purpose.
RESEARCH DESIGN AND
METHODS— The NHLBI-sponsored
PTCA and Dynamic Registries were pro-
spective multicenter studies that enrolled
patients undergoing coronary interven-
tions in centers from North America (7–
9). The 1985–1986 PTCA Registry
recruited 2,000 consecutive patients un-
dergoing de novo BA. The Dynamic Reg-
istry was initiated after the advent of BMS
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wavesof2,000patients(1:1997–1998,
n  2,524; 2: 1999, n  2,105; 3: 2001–
2002, n  2,047; 4: 2004, n  2,112; 5:
2006, n  2,178). Information on patient
characteristics and detailed angiographic
and procedural data were ascertained at
baseline. Written informed consent was
obtained from participants, all of whom
agreed to be contacted annually after dis-
charge. The study protocol was approved
by the Institutional Review Boards of the
coordinating center (University of Pitts-
burgh) and all the clinical sites.
Data on events including all-cause
death, MI, coronary artery bypass surgery
(CABG),andrepeatPCIwereascertained,
and hospital records were examined to
ensure consistency with protocol deﬁni-
tions. Speciﬁcally, the deﬁnition of MI
was revised to match prevailing expert
consensus; in the PTCA Registry, it was
deﬁned as evidence of two or more of the
following: 1) typical chest pain 20 min
not relieved by nitroglycerin, 2) serial
ECG recordings showing changes from
baseline or serially in ST-T and/or Q-
wavesintwoormorecontiguousleads,or
3) serum enzyme elevation of CK-MB
5%oftotalcreatininekinase(CK)(total
CK more than twice that of normal; LDH
subtype 1  LDH subtype 2); in the Dy-
namic Registry, cardiac troponin level
was incorporated as a major criteria.
This analysis was restricted to pa-
tients with reported diabetes at baseline.
In the PTCA Registry, history of diabetes
was ascertained through review of medi-
cal records by site coordinators and
through patient self-report. Baseline
treatmentstatus(insulinorhypoglycemic
agent versus diet controlled) was not
identiﬁed or recorded by site coordina-
tors (7). The Dynamic Registry identiﬁed
study patients with diabetes according to
the use of oral hypoglycemic agents, diet,
or treatment with insulin (9). Both regis-
tries did not explicitly identify the type of
diabetes (type 1 versus type 2). Patients
were then categorized by the type of de-
vice received (BA, BMS, or DES) at the
time of the index procedure. Because of
the availability of multiple treatment mo-
dalities in some recruitment waves, a se-
lection bias was anticipated. Given this,
BA patients were drawn from the PTCA
Registry and only from wave 1 of the Dy-
namic Registry, BMS patients were se-
lected from waves 1–3 of the Dynamic
Registry, and DES patients were from
waves 4 and 5 of the Dynamic Registry.
Patients who received both BA and BMS
were categorized as BMS, and those who
received both BMS and DES were classi-
ﬁed as DES.
Statistical methods
Differences in baseline patient and proce-
dural characteristics across the three de-
vice types were evaluated using the
Kruskal-Wallis test for continuous vari-
ables and the 
2 test for categorical vari-
ables. Kaplan-Meier (KM) estimates of
1-year event rates for combined death/MI
and repeat revascularizations (repeat PCI
or CABG) were compared using the log-
ranktest.Hazardratios(HRs)and95%CI
for events 31–365 days after index PCI
(“late” events) were estimated using Cox
regressionanalysismodelsfor1)BMSand
DES versus BA groups, and 2) DES versus
BMS groups. For multivariable adjust-
ment, only those data available in both
registries with signiﬁcant univariate dif-
ferencesacrossthethreedevicecategories
and outcomes were considered. All anal-
yseswereperformedwithSASversion9.1
(SAS Institute, Cary, NC).
RESULTS
Baseline patient characteristics
Table 1 shows baseline characteristics by
the type of device used for the 1,846 pa-
tients with diabetes who underwent de
novo PCI. On average, although the BMS
patients were older, patients who re-
ceived DES were more likely to report
concomitantcomorbidities(historyofhy-
pertension, dyslipidemia, and renal dis-
ease). No signiﬁcant differences were
notedinthetypeoftreatmentfordiabetes
among the BMS- and DES-treated
patients.
Angiographic, procedural, and lesion
characteristics
TheDESpatientsweremorelikelytohave
triple vessel disease and more signiﬁcant
lesions at baseline (Tables 2 and 3). Index
PCI in all three device groups was per-
formed more often for acute coronary
syndromes (BA 63%, BMS 69%, DES
65%; P  0.001) and as such, was more
often nonelective in nature. Among those
Table 1—Baseline patient characteristics by device type in 1,846 patients with diabetes
BA BMS DES P*
n 459 795 592
Age (years) 61.0  10.4 64.4  10.9 63.3  11.7 0.001
Female (%) 41 42 38 0.20
Prior CABG (%) 15 16 20 0.07
Prior MI (%) 40 25 15 0.001
BMI (kg/m
2) 29.1  5.7 30.5  6.2 32.0 7.0 0.001
Congestive heart failure (%) 14 15 14 0.81
Hypertension (%) 66 76 87 0.001
Hypercholesterolemia (%) 42 65 81 0.001
Treatment of diabetes (%)†
None — 5 4 0.51
Diet (no medical Rx) — 13 11
Oral medications (no insulin) — 52 54
Insulin — 30 31
Cigarette smoker (%)
Never 40.8 38.4 37.1 0.61
Current 20.6 19.2 19.5
Former 38.5 42.4 43.4
Severe noncardiac disease (%)† 17 44 46 0.001
Cerebrovascular — 8 9 0.58
Peripheral vascular disease — 11 10 0.54
Pulmonary — 10 8 0.26
Cancer — 8 9 0.72
Renal — 9 17 0.001
Other — 15 16 0.66
Data are means  SD and percentage unless otherwise indicated. *P value for differences in characteristics
across the device groups obtained using the Kruskal-Wallis test for continuous variables and 
2 test for
categorical variables; †P value is for differences between BMS and DES groups, as information on diabetes
treatment and subclasses of noncardiac disease were not collected in the NHLBI 1985–1986 PTCA Registry,
which comprises a major portion of BA group.
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portion of patients in cardiogenic shock
washigherintheBAgroup(BA32%,BMS
14%, DES 2%; P  0.001). Procedural
use of thienopyridine was higher in the
DES patients (BA 7%, BMS 57%, DES
87%; P  0.001). Attempted lesions
among DES-treated patients were more
oftenclassiﬁedastypeClesions(BA20%,
BMS 19%, DES 26%; P  0.001).
In-hospital and 1-year outcomes
Procedural success was achieved and
maintained more often with BMS and
DES compared with BA (BA 81%, BMS
97%, DES 99%; P  0.001), reﬂective of
technological advances. Rates of in-
hospital mortality, MI, and repeat revas-
cularizations were signiﬁcantly higher in
the BA group (Fig. 1A). The average
length of stay among patients alive at dis-
charge was higher for those in the BA
group (mean number of days: BA 4.2,
BMS 2.8, DES 2.1 days, P  0.001). The
prescribed use of recommended medica-
tions such as aspirin, ACE inhibitors,
-blockers, lipid-lowering therapy, and
antiplatelet therapy among those alive at
discharge was signiﬁcantly higher in the
BMS and DES groups (Fig. 1B).
Signiﬁcant differences were observed
in the 1-year unadjusted cumulative
eventratesbydevicetypefollowingindex
PCI. The overall incidence rates of
death/MI (BA 16%, BMS 13%, DES 10%;
P  0.01) and repeat PCI/CABG (BA
30%, BMS 20%, DES 13%; P  0.001)
were much lower in the BMS and DES
patients than in the BA groups. However,
therestrictionoftheanalysistolateevents
(31–365 days) revealed similar rates of
mortality or MI (Fig. 2). Multivariable
Cox regression analysis models compar-
ing BMS and DES with BA, and adjusting
for baseline characteristics, showed a
lower risk of mortality/MI, which did not
achieve statistical signiﬁcance for BMS
(Fig. 3). Further adjustment for the dis-
charge use of cardiac medications altered
the pattern for death/MI for DES, which
became statistically nonsigniﬁcant with
BA as reference (DES, HR 0.60 [95% CI
0.29–1.22]; P  0.16), and the risk of
repeatrevascularizationremainedstatisti-
cally signiﬁcant only with DES use with
BA as reference (DES, 0.57 [0.36–0.91];
P  0.02). Multivariable models compar-
ing DES to BMS use showed no statisti-
cally signiﬁcant difference in the risk of
death or MI but signiﬁcant reduction in
Table 2—Procedural by device type in 1,846 patients with diabetes
BA BMS DES P*
n 459 795 592
Ejection fraction 56.4  13.5 50.7  14.2 52.5  14.0 0.001
Number of vessels diseased (%)
Single 40 37 29 0.001
Double 29 34 32
Triple 32 30 40
Any total occlusion (%) 37 40 40 0.57
Signiﬁcant lesions 3.1  2.2 3.1  2.1 3.4  2.2 0.01
Amenable to complete revascularization
by PCI (%) 80 77 87 0.001
Amenable to complete revascularization
by CABG (%) 85 80 79 0.45
Primary reason for index PCI (%) 0.001
Asymptomatic coronary artery
disease/other reasons 7 13 18
Stable angina 30 19 18
Unstable angina 51 40 35
Acute myocardial infarction 12 29 30
Cardiogenic shock 32 14 2 0.001
Circumstances of procedure (%) 0.001
Elective 70 57 57
Urgent 23 31 33
Emergent 8 12 10
Number of vessels attempted (%) 0.01
Single vessel 77 81 74
Double vessels 16 11 19
Triple vessels 7 8 7
Number of lesions attempted (%)
1 64 67 65 0.13
2 2 42 52 6
31 3 8 9
Procedural use of clopidogrel or
ticlopidine (%) 7 57 87 0.001
Procedural use of glycoprotein IIb/IIIa
inhibitor (%) 6 40 35 0.001
Data are means  SD and percentages unless otherwise indicated. *P value for differences in characteristics
across the device groups obtained using the Kruskal-Wallis test for continuous variables and 
2 test for
categorical variables.
Table 3—Lesion characteristics by device type in 1,846 patients with diabetes
BA BMS DES P*
n 767 1,006 790
Lesion length (mm) 11.8  8.7 13.0  6.9 17.6 12.3 0.001
Preprocedure diameter stenosis (%) 83.4 14.4 83.7  13.3 83.7  10.8 0.18
Postprocedure diameter stenosis (%) 30.1  22.7 3.0  9.9 0.9  5.4 0.001
Evidence of thrombus 13 20 13 0.001
Ulcerated 7 16 14 0.01
Bifurcation 13 11 9 0.23
Calciﬁed 14 29 32 0.001
ACC/AHA Classiﬁcation
A 10 12 11 0.03
B1 32 35 33
B2 39 34 31
C 2 01 92 6
Data are percentages unless otherwise indicated. *P value for differences in characteristics across the device
groups obtained using the Kruskal-Wallis test for continuous variables and 
2 test for categorical variables.
ACC, American College of Cardiology; AHA, American Heart Association.
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(Fig. 3).
CONCLUSIONS — Using data from
the multicenter, NHLBI-sponsored PTCA
and Dynamic Registries, we describe the
characteristics of patients with diabetes
undergoing de novo PCI and compare
related outcomes across the three key
devices—BA,BMS,andDESintheﬁeld.
The proﬁle of patients and lesions un-
dergoing PCI today has expanded to in-
clude sicker cases with greater disease
burden. Compared with BA, patients
treatedwithBMSorDESwerealsomore
likely to be discharged on evidence-
based cardiac medications. Impor-
tantly, DES use was associated with a
comparable risk of death/MI once ad-
justed for pharmacotherapy in this
high-risk subset.
There have been questions regarding
theriskoflatestentthrombosisassociated
with DES in higher-risk patients, and the
danger of early discontinuation of anti-
platelet therapy (10). Recent data from
Europe however has shown that com-
pared with BMS, DES is associated with a
similar long-term incidence of death or
MI but provides a clinically important re-
duction in the rate of restenosis among
high-risk patients (11). Our analysis
found signiﬁcant reductions in the need
for repeat revascularization with DES use
compared with BA and BMS and no dif-
ference in death/MI once adjusted for
pharmacotherapy.
Unrestricted use of DES has been
showntohavebetteroutcomesthanBMS,
withfewerclinicallydrivenrevasculariza-
tion procedures and similar rates of death
and MI at 1 year (12). However, pooled
analyses in patients with diabetes have
shown conﬂicting results regarding sur-
vival when comparing BMS- and DES-
treatedpatients(5,6).Inapreviousreport
from the 1997–1999 Dynamic Registry
patientswithdiabeteswereshowntohave
Figure 1—In-hospital outcomes (A) and discharge medication* use (B) after PCI by device type in patients with diabetes. *Percentages of
antiplatelets and lipid-lowering drugs predominantly reﬂect information from the NHLBI-sponsored Dynamic Registry patients.
Rana and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 1979had a signiﬁcantly higher adjusted risk of
mortality and need for repeat revascular-
ization than those without diabetes (13).
AnotherstudyfromtheDynamicRegistry
comparedtheefﬁcacyofDESwithBMSin
patients with insulin- and non–insulin-
treateddiabetesandshowedthatDESwas
associated with a lower risk for repeat re-
vascularization compared with BMS in
bothinsulin-andnon–insulin-treatedpa-
tients (14). More recent data from this
group extended these ﬁndings to show
that, among this high-risk subset, PCI
outcomes did not differ by the type of
DES (sirolimus- or paclitaxel-eluting)
used (15).
Pharmacotherapy has also evolved
over recent decades and has contributed
to the reduction in the number of cardiac
deaths (16). The impact of the evolution
ofbothdevicesandpharmacotherapy,es-
pecially among patients with diabetes un-
dergoing PCI over the last 3 decades,
remains a matter of interest. Our study
explored the use of pharmacotherapy at
discharge to show that recommended
medications such as aspirin, ACE inhibi-
tors, -blockers, lipid-lowering therapy,
and antiplatelet therapy is considerably
higher in the BMS and DES groups and
may have played an important role in the
observed favorable outcomes in these
groups.
Study limitations
For the purposes of this analysis, only
those variables available in both the reg-
istries were considered. Compared with
the PTCA Registry, ascertainment of data
in the Dynamic Registry was revised to
incorporate information related to the
prevailing concerns in the ﬁeld. Speciﬁ-
cally, data regarding the treatment of dia-
betes and presence of renal disease or
biochemical parameters of renal function
were unavailable in the PTCA Registry,
thuslimitingourabilitytoaccountfordif-
ferences in these parameters. Information
on duration of diabetes, extent of glucose
controls, or speciﬁc dosages of discharge
pharmacotherapy was also not available.
The registries did not specify, a priori, es-
timates of detectable effect sizes for indi-
vidualdevicesusedorsubgroupanalyses.
Nonetheless, post hoc power calculations
based on the observed late event rates
showed an 80% power (two-sided type I
error rate of 0.05 and 5% lost to follow-
up) to detect modest-to-large effect sizes
of 0.46 and 0.63 for death/MI and repeat
revascularization, respectively, with DES
use compared with BA use. Finally, as
with all observational studies, there may
be residual confounding not fully ac-
counted for in the standard multivariable
analyses.
In conclusion, our report from the
large, prospective, multicenter, NHLBI-
sponsored 1985–1986 PTCA (BA era)
and 1997–2006 Dynamic Registry (BMS
and DES era) documents the rapid evolu-
tion in PCI treatment options for patients
with diabetes. Contemporary devices of
PCIwereusedmoreofteninpatientswith
severe comorbidities and multivessel dis-
ease and were associated with improved
discharge use of recommended cardiac
medications.Inpatientswithdiabetesun-
Figure2—Cumulative(Kaplan-Meier)eventratesfordeath/MI(A)andrepeatrevascularization(B)bydevicetypeat1yearand31–365daysafter
discharge.
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withareducedneedforrepeatrevascular-
ization when compared with angioplasty
orBMSuse.Theassociateddeath/MIben-
eﬁt observed with th eDES versus the BA
group may well be due to greater use of
pharmacotherapy.
Acknowledgments— No potential conﬂicts
of interest relevant to this article were
reported.
J.S.R. and L.V. wrote the manuscript and
planned and performed analyses. F.S. and
K.E.K. planned the analyses and reviewed/
edited the manuscript. R.W.N. concieved the
idea, reviewed/edited the manuscript, and
contributed to all sections of the manuscript.
S.R.M., O.C.M., W.K.L., E.M.H., V.S.S., and
S.F.K. reviewed/edited the manuscript.
References
1. Venkitachalam L, Kip KE, Selzer F,
WilenskyRL,SlaterJ,MulukutlaSR,Mar-
roquin OC, Block PC, Williams DO,
Kelsey SF, Investigators of NHLBI-Spon-
sored 1985–1986 PTCA and 1997–2006
Dynamic Registries. Twenty-year evolu-
tion of percutaneous coronary interven-
tionanditsimpactonclinicaloutcomes:a
reportfromtheNHLBI-sponsored,multi-
center 1985–86 PTCA and 1997–2006
Dynamic Registries. Circ Cardiovasc In-
terv 2009;2:6–13
2. StettlerC,WandelS,AllemannS,Kastrati
A, Morice MC, Scho ¨mig A, Pﬁsterer ME,
Stone GW, Leon MB, de Lezo JS, Goy JJ,
ParkSJ,Sabate ´ M,SuttorpMJ,KelbaekH,
Spaulding C, Menichelli M, Vermeersch
P, Dirksen MT, Cervinka P, Petronio AS,
Nordmann AJ, Diem P, Meier B, Zwahlen
M, Reichenbach S, Trelle S, Windecker S,
Ju ¨ni P. Outcomes associated with drug-
elutingandbare-metalstents:acollabora-
tive network meta-analysis. Lancet 2007;
370:937–948
3. Stein B, Weintraub WS, Gebhart SP, Co-
hen-Bernstein CL, Grosswald R, Liber-
man HA, Douglas JS Jr, Morris DC, King
SB 3rd. Inﬂuence of diabetes mellitus on
earlyandlateoutcomeafterpercutaneous
transluminalcoronaryangioplasty.Circu-
lation 1995;91:979–989
4. Abizaid A, Kornowski R, Mintz GS,
Hong MK, Abizaid AS, Mehran R, Pi-
chard AD, Kent KM, Satler LF, Wu H,
Popma JJ, Leon MB. The inﬂuence of
diabetes mellitus on acute and late clin-
ical outcomes following coronary stent
implantation. J Am Coll Cardiol 1998;
32:584–589
5. Spaulding C, Daemen J, Boersma E, Cut-
lip DE, Serruys PW. A pooled analysis of
data comparing sirolimus-eluting stents
with bare-metal stents. N Engl J Med
2007;356:989–997
6. Kastrati A, Mehilli J, Pache J, Kaiser C,
Valgimigli M, Kelbaek H, Menichelli M,
Sabate ´ M, Suttorp MJ, Baumgart D, Sey-
farth M, Pﬁsterer ME, Scho ¨mig A. Analy-
sis of 14 trials comparing sirolimus-
eluting stents with bare-metal stents.
N Engl J Med 2007;356:1030–1039
7. Kip KE, Faxon DP, Detre KM, Yeh W,
Kelsey SF, Currier JW. Coronary angio-
plasty in diabetic patients. The National
Heart, Lung and Blood Institute Percutane-
Figure 3—Univariate and adjusted HRs (95% CI) for “late” (31–365 days) outcomes after percutaneous intervention by device type. *Adjusted for
age, BMI, prior CABG, prior MI, history of hypertension, history of hypercholesterolemia, cardiogenic shock, severe noncardiac disease, vessel
disease(single/double/triple),meannumberofsigniﬁcantlesions,circumstancesofindexPCI,primaryreasonforindexPCI(stableangina,unstable
angina/acute MI asymptomatic CAD/others) and †discharge use of aspirin, -blockers, lipid-lowering medications, ACE inhibitors, or angiotensin
receptor blockers; thienopyridines were included only in models comparing BMS and DES.
Rana and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 1981ous Transluminal Coronary Angioplasty
Registry. Circulation 1996;94:1818–1825
8. Williams DO, Holubkov R, Yeh W,
Bourassa MG, Al-Bassam M, Block PC,
Coady P, Cohen H, Cowley M, Dorros
G, Faxon D, Holmes DR, Jacobs A,
KelseySF,KingSB3rd,MylerR,SlaterJ,
Stanek V, Vlachos HA, Detre KM. Per-
cutaneous coronary intervention in the
current era compared with 1985–1986:
the National Heart, Lung and Blood In-
stituteRegistries.Circulation2000;102:
2945–2951
9. Laskey WK, Williams DO, Vlachos HA,
Cohen H, Holmes DR, King SB 3rd,
KelseySF,SlaterJ,FaxonD,Al-BassamM,
Block E, Detre KM, Dynamic Registry In-
vestigators. Changes in the practice of
percutaneous coronary intervention: a
comparison of enrollment waves in the
National Heart, Lung, and Blood Institute
(NHLBI) Dynamic Registry. Am J Cardiol
2001;87:964–969
10. Kaul S, Shah PK, Diamond GA. As time
goes by: current status and future direc-
tions in the controversy over stenting.
J Am Coll Cardiol 2007;50:128–137
11. JamesSK,StenestrandU,LindbackJ,Carls-
son J, Schersten F, Nilsson T, Wallentin L,
Lagerqvist B. SCAAR Study Group: Long-
termsafetyandefﬁcacyofdrug-elutingver-
sus baremetal stents in Sweden. N Engl
J Med 2009;7;360:1933–1945
12. AbbottJD,VossMR,NakamuraM,Cohen
HA,SelzerF,KipKE,VlachosHA,Wilen-
sky RL, Williams DO. Unrestricted use of
drug-eluting stents compared with bare-
metal stents in routine clinical practice:
ﬁndings from the National Heart, Lung,
and Blood Institute Dynamic Registry.
J Am Coll Cardiol 2007;50:2029–2036
13. LaskeyWK,SelzerF,VlachosHA,Johnston
J,JacobsA,KingSB3rd,HolmesDR,Doug-
las J, Block P, Wilensky R, Williams DO,
Detre K, Dynamic Registry Inverstigators.
Dynamic Registry Inverstigators. Compari-
sonofin-hospitalandone-yearoutcomesin
patients with and without diabetes mellitus
undergoing percutaneous catheter inter-
vention (from the National Heart, Lung,
and Blood Institute Dynamic Registry).
Am J Cardiol 2002;90:1062–1067
14. Mulukutla SR, Vlachos HA, Marroquin
OC, Selzer F, Holper EM, Abbott JD, Las-
key WK, Williams DO, Smith C, Ander-
sonWD,LeeJS,SrinivasV,KelseySF,Kip
KE. Impact of drug-eluting stents among
insulin-treated diabetic patients: a report
fromtheNationalHeart,Lung,andBlood
InstituteDynamicRegistry.JACCCardio-
vasc Interv 2008;1:139–147
15. Wolf WM, Vlachos HA, Marroquin OC,
LeeJS,SmithC,AndersonWD,Schindler
JT, Holper EM, Abbott JD, Williams DO,
Laskey WK, Kip KE, Kelsey SF, Mulukutla
SR. Paclitaxel-eluting versus sirolimus-
eluting stents in diabetes mellitus: a re-
port from the National Heart, Lung and
Blood Institute Dynamic Registry. Circ
Cardiovasc Interv 2010;3:42–49
16. Ford ES, Ajani UA, Croft JB, Critchley JA,
Labarthe DR, Kottke TE, Giles WH,
Capewell S. Explaining the decrease in U.S.
deaths from coronary disease, 1980–2000.
N Engl J Med 2007;356:2388–2398
Evolution of percutaneous coronary intervention
1982 DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 care.diabetesjournals.org